The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib
- PMID: 21504411
- DOI: 10.2174/138161211796197124
The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib
Abstract
Proteasome inhibition is a modern and surprisingly successful approach how to cancer treatment. Bortezomib (Velcade®) is a first-in-class proteasome inhibitor and has been approved for first-line treatment of multiple myeloma and second-line treatment of mantle cell lymphoma. There have been almost 200 clinical trials with bortezomib, both as a single agent and in combination with other drugs, for various cancers, as listed in the US National Cancer Institute database. However, bortezomib's mechanism of action remains elusive despite enormous progress in our knowledge of the cell biology of the ubiquitin-proteasome system (UPS) and bortezomib-induced signaling events in cancer cells. This review maps a rapidly growing and open body of research in both areas.
Similar articles
-
Novel proteasome inhibitors to overcome bortezomib resistance.J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. doi: 10.1093/jnci/djr160. Epub 2011 May 23. J Natl Cancer Inst. 2011. PMID: 21606441 Review.
-
[Proteasome inhibitor].Nihon Rinsho. 2010 Jun;68(6):1079-84. Nihon Rinsho. 2010. PMID: 20535959 Review. Japanese.
-
Proteasome inhibitors.Prog Mol Biol Transl Sci. 2012;109:161-226. doi: 10.1016/B978-0-12-397863-9.00005-5. Prog Mol Biol Transl Sci. 2012. PMID: 22727422 Review.
-
The proteasome: a novel _target for anticancer therapy.Clin Transl Oncol. 2006 May;8(5):313-7. doi: 10.1007/s12094-006-0176-8. Clin Transl Oncol. 2006. PMID: 16760005 Review.
-
Development of the proteasome inhibitor Velcade (Bortezomib).Cancer Invest. 2004;22(2):304-11. doi: 10.1081/cnv-120030218. Cancer Invest. 2004. PMID: 15199612 Review.
Cited by
-
Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment.J R Soc Interface. 2021 Jan;18(174):20200669. doi: 10.1098/rsif.2020.0669. Epub 2021 Jan 6. J R Soc Interface. 2021. PMID: 33402021 Free PMC article.
-
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.Anticancer Drugs. 2013 Nov;24(10):1030-8. doi: 10.1097/CAD.0000000000000008. Anticancer Drugs. 2013. PMID: 23995855 Free PMC article.
-
Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.PLoS One. 2013 Apr 17;8(4):e61446. doi: 10.1371/journal.pone.0061446. Print 2013. PLoS One. 2013. PMID: 23613854 Free PMC article.
-
Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.Int J Mol Sci. 2018 Mar 14;19(3):855. doi: 10.3390/ijms19030855. Int J Mol Sci. 2018. PMID: 29538325 Free PMC article. Review.
-
Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system.Invest New Drugs. 2013 Jun;31(3):587-98. doi: 10.1007/s10637-012-9902-y. Epub 2012 Nov 20. Invest New Drugs. 2013. PMID: 23179339
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
